Association_NN
of_IN
TRAF1_NN
,_,
TRAF2_NN
,_,
and_CC
TRAF3_NN
with_IN
an_DT
Epstein-Barr_JJ
virus_NN
LMP1_NN
domain_NN
important_JJ
for_IN
B-lymphocyte_NN
transformation_NN
:_:
role_NN
in_IN
NF-kappaB_NN
activation_NN
._.

The_DT
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
transforming_VBG
protein_NN
LMP1_NN
appears_VBZ
to_TO
be_VB
a_DT
constitutively_RB
activated_VBN
tumor_NN
necrosis_NN
factor_NN
receptor_NN
-LRB-_-LRB-
TNFR_NN
-RRB-_-RRB-
on_IN
the_DT
basis_NN
of_IN
an_DT
intrinsic_JJ
ability_NN
to_TO
aggregate_NN
in_IN
the_DT
plasma_NN
membrane_NN
and_CC
an_DT
association_NN
of_IN
its_PRP$
cytoplasmic_JJ
carboxyl_NN
terminus_NN
-LRB-_-LRB-
CT_NN
-RRB-_-RRB-
with_IN
TNFR-associated_JJ
factors_NNS
-LRB-_-LRB-
TRAFs_NNS
-RRB-_-RRB-
._.

We_PRP
now_RB
show_VBP
that_IN
in_IN
EBV-transformed_JJ
B_NN
lymphocytes_NNS
most_JJS
of_IN
TRAF1_NN
or_CC
TRAF3_NN
and_CC
5_CD
%_NN
of_IN
TRAF2_NN
are_VBP
associated_VBN
with_IN
LMP1_NN
and_CC
that_IN
most_JJS
of_IN
LMP1_NN
is_VBZ
associated_VBN
with_IN
TRAF1_NN
or_CC
TRAF3_NN
._.

TRAF1_NN
,_,
TRAF2_NN
,_,
and_CC
TRAF3_NN
bind_VBP
to_TO
a_DT
single_JJ
site_NN
in_IN
the_DT
LMP1_NN
CT_NN
corresponding_VBG
to_TO
amino_NN
acids_NNS
-LRB-_-LRB-
aa_NNS
-RRB-_-RRB-
199_CD
to_TO
214_CD
,_,
within_IN
a_DT
domain_NN
which_WDT
is_VBZ
important_JJ
for_IN
B-lymphocyte_NN
growth_NN
transformation_NN
-LRB-_-LRB-
aa_NNS
187_CD
to_TO
231_CD
-RRB-_-RRB-
._.

Further_JJ
deletional_JJ
and_CC
alanine_NN
mutagenesis_NN
analyses_NNS
and_CC
comparison_NN
with_IN
TRAF_NN
binding_NN
sequences_NNS
in_IN
CD40_NN
,_,
in_IN
CD30_NN
,_,
and_CC
in_IN
the_DT
LMP1_NN
of_IN
other_JJ
lymphycryptoviruses_NNS
provide_VBP
the_DT
first_JJ
evidence_NN
that_IN
PXQXT\/S_NN
is_VBZ
a_DT
core_NN
TRAF_NN
binding_NN
motif_NN
._.

The_DT
negative_JJ
effects_NNS
of_IN
point_NN
mutations_NNS
in_IN
the_DT
LMP1_NN
-LRB-_-LRB-
1-231_NN
-RRB-_-RRB-
core_NN
TRAF_NN
binding_NN
motif_NN
on_IN
TRAF_NN
binding_NN
and_CC
NF-kappaB_NN
activation_NN
genetically_RB
link_VBP
the_DT
TRAFs_NNS
to_TO
LMP1_NN
-LRB-_-LRB-
1-231_CD
-RRB-_-RRB-
-_:
mediated_JJ
NF-kappaB_NN
activation_NN
._.

NF-kappaB_NN
activation_NN
by_IN
LMP1_NN
-LRB-_-LRB-
1-231_CD
-RRB-_-RRB-
is_VBZ
likely_JJ
to_TO
be_VB
mediated_VBN
by_IN
TRAF1\/TRAF2_NN
heteroaggregates_NNS
since_IN
TRAF1_NN
is_VBZ
unique_JJ
among_IN
the_DT
TRAFs_NNS
in_IN
coactivating_VBG
NF-kappaB_NN
with_IN
LMP1_NN
-LRB-_-LRB-
1-231_CD
-RRB-_-RRB-
,_,
a_DT
TRAF2_NN
dominant-negative_JJ
mutant_NN
can_MD
block_VB
LMP1_NN
-LRB-_-LRB-
1-231_CD
-RRB-_-RRB-
-_:
mediated_JJ
NF-kappaB_NN
activation_NN
as_RB
well_RB
as_IN
TRAF1_NN
coactivation_NN
,_,
and_CC
30_CD
%_NN
of_IN
TRAF2_NN
is_VBZ
associated_VBN
with_IN
TRAF1_NN
in_IN
EBV-transformed_JJ
B_NN
cells_NNS
._.

TRAF3_NN
is_VBZ
a_DT
negative_JJ
modulator_NN
of_IN
LMP1_NN
-LRB-_-LRB-
1-231_CD
-RRB-_-RRB-
-_:
mediated_JJ
NF-kappaB_NN
activation_NN
._.

Surprisingly_RB
,_,
TRAF1_NN
,_,
-2_CD
,_,
or_CC
-3_CD
does_VBZ
not_RB
interact_VB
with_IN
the_DT
terminal_JJ
LMP1_NN
CT_NN
aa_NNS
333_CD
to_TO
386_CD
which_WDT
can_MD
independently_RB
mediate_VB
NF-kappaB_NN
activation_NN
._.

The_DT
constitutive_JJ
association_NN
of_IN
TRAFs_NNS
with_IN
LMP1_NN
through_IN
the_DT
aa_NN
187_CD
to_TO
231_CD
domain_NN
which_WDT
is_VBZ
important_JJ
in_IN
NF-kappaB_NN
activation_NN
and_CC
primary_JJ
B-lymphocyte_NN
growth_NN
transformation_NN
implicates_VBZ
TRAF_NN
aggregation_NN
in_IN
LMP1_NN
signaling_NN
._.

